Smith & Nephew PLC (SN.) — Investment Research Note

Executive summary

Smith+Nephew is a UK-listed global medical-technology company operating across three franchises — Orthopaedics (hip/knee implants, robotics, trauma), Sports Medicine & ENT, and Advanced Wound Management — generating $6.2bn of 2025 revenue predominantly in USD. Across the filing period the group has delivered its "12-Point Plan" turnaround: underlying revenue growth accelerated from ~2% (2022) to 5.3% (2025), trading margin expanded from 17.3% to 19.7%, free cash flow rose fifteen-fold to $840m, and management set 2028 targets of 6-7% CAGR and 9-10% trading profit CAGR under the new "RISE" strategy. The single most important point for valuation today is that FY26 revenue guidance was cut in August from ~6% to ~4% growth on US Orthopaedics and skin-substitute headwinds — the shares now sit near 52-week lows and trade on ~12x forward EPSA versus mid-cap med-tech peers at 15-20x, offering value if the H2 acceleration into new launches (LANDMARK, ALLEVYN COMPLETE CARE, CATALYSTEM) materialises.

Fair value estimate

• Fair value range: 1,100p – 1,400p per share (midpoint ~1,250p)
• Implied market cap range: £9,207m – £11,718m (mid ~£10,463m)
• Methodology: blended forward EPSA multiple (12-15x on ~110¢ FY26E EPSA, implying ~830p-1,040p on that lens) and EV/EBIT (12-14x on FY26 trading profit ~$1.3bn less $3bn net debt, implying 1,150p-1,450p). I have weighted EV/EBIT more heavily given the strong FCF conversion post 12-Point Plan and net debt/EBITDA of 1.8x is comfortably serviceable.
• Key assumptions: FY26 trading profit delivered at ~$1.3bn guide, FCF conversion sustains ~80%, USD/GBP ~1.32, ROIC steps toward 12-13% by 2028 as guided
• Comparison to current market cap of £8,600m: mid fair value implies ~22% upside; range spans +7% to +36%
• View: undervalued on central case, though modestly so given the execution risk in US Orthopaedics

Sector context

• Sector classification confirmed: Health Care / Medical Devices (large-cap medtech). The RISE strategy positions the group as a mid-tier reconstruction/wound player, structurally smaller and lower margin than Stryker or Medtronic
• Quality profile: Below sector best-in-class — trading margin (~19-20%) trails Stryker (~26%) and Zimmer Biomet (~28% adj), and US Reconstruction growth continues to lag peers. Balance sheet leverage (1.8x) is in line with peers
• Listed peers: Stryker (SYK), Zimmer Biomet (ZBH), Medtronic (MDT); closer share-of-portfolio peers include ConvaTec (wound) and Integra LifeSciences

Investment thesis

• 12-Point Plan is now delivering measurable financial outcomes — 240bps of trading margin expansion since 2022 despite ~1,000bps of cumulative macro headwinds; $330m of the $325-375m 2027 savings target already realised; H1 2026 delivered 11% EPSA growth on only 2.3% underlying revenue growth 2026-08 half-year
• RISE strategy sets a credible mid-term step-up — 2028 targets of 6-7% revenue CAGR, 9-10% trading profit CAGR, $1bn+ FCF and 12-13% adj ROIC, underpinned by high-cadence launches (LANDMARK cementless knee H2 2026, CATALYSTEM hips, AETOS shoulder, TESSA AR/AI arthroscopy platform, ALLEVYN COMPLETE CARE), plus $500m active buyback signalling capital-return confidence 2026-03 final results; 2026-08 half-year
• Sports Medicine and Advanced Wound Management (~60% of group) continue to outperform — Sports Medicine grew 8.6% underlying in Q2 2026 with a 160bps margin uplift to 24.7%; Integrity Orthopaedics acquisition adds Tendon Seam, complementing REGENETEN in a $875m US rotator-cuff market with 20-40% traditional failure rates 2026-01 acquisition; 2026-08 half-year

Key risks

• US Orthopaedics remains structurally slow — US Knee Implants declined -7.2% in Q2 2026 and -10.3% in Q1 2026, driving the FY26 revenue cut from ~6% to ~4%. LANDMARK launch execution is the swing factor and is not yet proven 2026-08 half-year; 2026-05 Q1 update
• Skin substitute reimbursement reset in the US — Advanced Wound Bioactives fell -12.7% underlying in Q2 2026 and management now expects the FY26 headwind at the "upper end" of $20-40m; competitive/pricing dynamics in non-surgical mobile channel remain fluid 2026-08 half-year
• China VBP overhang and geopolitical tariff exposure — Sports Medicine ENT China faces further VBP rounds in H2 2026; management guided tariff impact at ~$60m gross for 2026, now offset by refunds but exposure remains binary on trade policy 2026-03 final results

Operating leverage

Smith+Nephew is a moderately leveraged operator, not a high-leverage software or platform business. Trading gross margin sits at 70.9% (H1 2026), with a fixed-cost R&D burden of ~5% of revenue, a broad sales-force footprint of 17,000 employees, and heavy instrument-set/inventory intensity in Orthopaedics. Trading profit margin has expanded 60bps to 18.3% in H1 2026 despite lower revenue growth, showing incremental savings drop-through of roughly 50-60% of announced $50m efficiencies. On the 2028 model, ~$1bn of incremental revenue at 6-7% CAGR is guided to translate to $220-250m of incremental trading profit (~22-25% incremental margin), which is decent but not the multiple-of-profit dynamic the investor is seeking. A 10-20% upside revenue surprise from current base would plausibly deliver 20-40% profit upside — meaningful but not the "long-tail" outcome available in specialised software. Fixed manufacturing footprint (new Melton UK wound facility 2027, new Malaysia orthopaedics) is the primary source of scale leverage over the medium term 2026-08 half-year; 2026-03 final results; 2025-12 CMD.

Value-trap signals

None identified — revenue is growing, dividend is progressive (+4% at H1 2026), leverage is comfortable at 1.8x, FCF conversion has recovered to ~85-90% on plan, and disclosure is high quality. Legal metal-on-metal hip provisions are declining, not building. The US Knee under-performance is a genuine execution issue but the wider portfolio is compounding.

Earnings vs. expectations

• FY 2025 (Mar 2026 results): guided ~5% underlying growth / >18% trading margin — delivered 5.3% growth / 19.7% margin — beat on both
• Q1 2026 (May 2026): reiterated FY guidance of ~6% growth / ~$1.3bn trading profit; announced $500m buyback — met guidance, positive tone
• H1 2026 (Aug 2026): missed on revenue (guidance cut from ~6% to ~4%), but beat on profit growth (+8.1% trading profit) and reiterated $1.3bn trading profit and $800m FCF guidance
• Pattern: management has a credible record of protecting profit and cash even when revenue disappoints. Consensus-referenced beats are less clearly disclosed, but management-guidance track record is roughly two-thirds "meet or beat" on profit and mixed on revenue during 2024-26, with H1 2026 the most notable revenue miss.

Conviction

Conviction: 4 (high)

• Anchors: (a) transparent financial disclosure including reconciled non-IFRS measures and clear segmental trading profit; (b) five years of consistent methodology and a well-defined 12-Point Plan / RISE roadmap; (c) two independent valuation lenses (EV/EBIT and forward EPSA) triangulate to similar ranges
• Limits: (a) FY26 revenue guidance was just cut, so central-case trading profit hinges on H2 acceleration and LANDMARK launch success; (b) reported vs. trading profit gap remains large (~$260m of adjustments in 2025), keeping some subjectivity in the EPSA anchor

Overall assessment for this investor

Smith+Nephew fits the "valuation discipline" pillar well — it is not priced for perfection and offers ~20% upside on a conservative central case with a well-covered ~3.5% dividend and active buyback. It scores poorly on the AI-receiver pillar: while it uses AI in the TESSA arthroscopy platform and CORI robotics, the value capture flows overwhelmingly from surgical innovation, not from AI infrastructure spending. Operating leverage is moderate rather than high — a 10-20% revenue surprise gives ~1.5-2x profit uplift, not multiples of profit. Downside protection is solid.